GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Agilent Technologies, Inc. (A) [hlAlert]

Rating:
Outperform
A
down 14.96 %

Agilent Technologies, Inc. (A) rated Outperform by Leerink Swann

Posted on: Wednesday,  Mar 6, 2013  8:25 AM ET by Leerink Swann

Leerink Swann rated Outperform Agilent Technologies, Inc. (NYSE: A) on 03/06/2013, when the stock price was $43.09.
Since then, Agilent Technologies, Inc. has lost 14.97% as of 01/07/2016's recent price of $36.64.
If you would have followed this Leerink Swann 's recommendation on A, you would have lost 14.96% of your investment in 1037 days.

Agilent Technologies, Inc. is a measurement company providing bio-analytical and electronic measurement solutions to the communications, electronics, life sciences and chemical analysis industries. The Company operates in two business segments: electronic measurement business and the bio-analytical measurement business. The electronic measurement business provides standard and customized electronic measurement instruments and systems monitoring, management and optimization tools for communications networks and services, software design tools and related services that are used in the design, development, manufacture, installation, deployment and operation of electronics equipment and communications networks and services. The bio-analytical measurement business provides application-focused solutions that include instruments, software, consumables and services that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/6/2013 8:25 AM Buy
None
43.09
as of 12/13/2013
1 Week up  0.60 %
1 Month up  7.73 %
3 Months up  13.82 %
1 YTD up  28.01 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy